Vicarious Surgical Names Stephen From as New CEO, Prepares for Human Trials

Vicarious Surgical, a developer of surgical robots, has announced a significant leadership change as it approaches a crucial phase in its product development. The company has appointed Stephen From as its new CEO, effective August 7, 2025, replacing co-founder Adam Sachs, who will transition to the role of company president while retaining his board membership.

From's Appointment and Background

Stephen From brings over two decades of leadership experience in the healthcare and financial industries to Vicarious Surgical. Most recently, From served as CEO of Aruna Bio, a biotech firm focused on developing neural exosomes for the treatment of neurodegenerative diseases. His prior roles include executive chairman of Kiora Pharmaceuticals (formerly EyeGate Pharmaceuticals), where he oversaw an initial public offering and multiple acquisitions and licensing transactions. From's experience also extends to his time as CFO of Centelion, a former biotech subsidiary of Sanofi-Aventis, and his years in investment banking with a focus on the life sciences sector.

Adam Sachs, the outgoing CEO, expressed confidence in From's appointment, stating, "I believe his leadership and experience are exactly what we need at this pivotal stage."

Company Developments and Future Plans

Vicarious Surgical is currently preparing for a significant milestone: the first human cases using its robotic surgery system. The company is advancing through the necessary approval processes to perform these procedures, with its pivotal trial focusing on ventral hernia repair.

Despite these advancements, Vicarious Surgical has faced some setbacks. The company previously delayed its expected de novo submission to the Food and Drug Administration, pushing the timeline to late 2026. This delay highlights the complex regulatory landscape surrounding innovative medical devices.

In a strategic move to promote adoption of its robotic surgery system, Vicarious Surgical is collaborating with UMass Memorial Medical Center, the flagship hospital of the UMass Memorial Health system. This partnership could prove crucial in demonstrating the system's efficacy and gaining traction in the competitive surgical robotics market.

As Vicarious Surgical navigates these challenges and opportunities, the appointment of Stephen From as CEO signals the company's commitment to leveraging experienced leadership to guide its next phase of growth and development in the rapidly evolving field of robotic surgery.